Recent advances in breast cancer biology

Current Opinion in Oncology

Volumn 11, Issue 6, 1999, Pages 429-434

  Schultz, Linda B ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DNA;

APOPTOSIS; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER GENETICS; DNA REPAIR; GENETIC PREDISPOSITION; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL;

EID: 0032720340     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199911000-00002     Document Type: Review

References (64)

1. 1 Szabo CI, King MC: Inherited breast and ovarian cancer. Hum Mol Genet 1995, 4:1811-1817.
2. 2 Stratton MR, Wooster R: Hereditary predisposition to breast cancer. Curr Opin Genet Dev 1996, 6:93-97.
3. 3 Easton DF, Bishop DT, Ford D, Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993, 52:678-701.
4. 4 Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408.
5. 5 Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, et al.: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998, 63:45-51.
6. 6 Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265-271.
7. 7 Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, et al.: Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995, 64:394-398.
8. 8 Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al.: Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999, 64:1371-1377. This excellent, well-controlled study supports the hypothesis that BRCA1 modifier genes exist.
9. 9 Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997, 6:733-743.
10. 10 Zhu X, Daffada AA, Chan CM, Dowsett M: Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer 1997, 72:574-580.
11. 11 Birrell S, Hall R, Tilley W: Role of the androgen receptor in human breast cancer. J Mamm Gland Biol Neoplasia 1998, 3:95-103.
12. 12 Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigan S, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
13. 13 Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV: A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997, 11:68-76.
14. 14 Callebaut I, Mornon JP: From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett 1997, 400:25-30.
15. 15 Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al.: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997, 336:1409-1415.
16. 16 Hsu LC, White RL: BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci U S A 1998, 95:12983-12988. This was the first study to show an association between BRCA1 and the centrosome.
17. 17 Bailly E, Pines J, Hunter T, Bornens M: Cytoplasmic accumulation of cyclin B1 in human cells: association with a detergent-resistant compartment and with the centrosome. J Cell Sci 1992, 101:529-545.
18. 18 Bailly E, Doree M, Nurse P, Bornens M: p34cdc2 is located in both nucleus and cytoplasm: part is centrosomally associated at G2/M and enters vesicles at anaphase. EMBO J 1989, 8:3985-3995.
19. 19 Pockwinse SM, Krockmalnic G, Doxsey SJ, Nickerson J, Lian JB, van Wijnen AJ, et al.: Cell cycle independent interaction of CDC2 with the centrosome, which is associated with the nuclear matrix-intermediate filament scaffold. Proc Natl Acad Sci U S A 1997, 94(7):3022-3027.
20. 20 Pietromonaco SF, Seluja GA, Aitken A, Elias L: Association of 14-3-3 proteins with centrosomes. Blood Cells Mol Dis 1996, 22:225-237.
21. 21 Brown CR, Doxsey SJ, White E, Welch WJ: Both viral (adenovirus E1B) and cellular (hsp 70, p53) components interact with centrosomes. J Cell Physiol 1994, 160:47-60.
22. 22 Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF: Abnormal centrosome amplification in the absence of P53. Science 1996, 271:1744-1777.
23. 23 Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, et al.: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999, 3:389-395. This well-controlled study documents a defective G2-M checkpoint, chromosomal abnormalities, multiple centrosomes, and aneuploidy in mouse embryo fibroblasts with a targeted deletion of BRCA1.
24. 24 Meyn MS: Chromosome instability syndromes: lessons for carcinogenesis. Curr Top Microbiol Immunol 1997, 221:71-148.
25. 25 Yarden RI, Bordy LC: BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999, 96:4983-4988. The interaction of BRCA1 with components of the histone deacetylase complex, retinoblastoma protein, and retinoblastoma protein-binding proteins is documented.
26. 26 Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al.: Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999, 97:575-586. This elegant study suggests a p53-independent BRCA1-induced apoptotic pathway.
27. 27 Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998, 281:1009-1012. This study indicates that BRCA1 participates in transcription-coupled repair of DNA damage induced by ionizing radiation or oxidative damage but not by ultraviolet radiation.
28. 28 Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT: BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement transcription-coupled repair. J Biol Chem 1999, 274:18808-18812. This study documents that human cancer cells containing mutated BRCA1 are hypersensitive to ionizing radiation that can be reversed by the expression of nonmutated forms of BRCA1.
29. 29 Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH: BRCA1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996 12:191-194.
30. 30 Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, et al.: The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85:1009-1023.
31. 31 Liu C, Flesken-Nikitin A, Li S, Zeng Y, Lee WH: Inactivation of the mouse BRCA1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 1996, 10:1835-1843.
32. 32 Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, et al: Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22:37-43. This elegant paper describes the first significant model system to study the genetic pathways dysregulated in familial breast cancer.
33. 33 Shiloh Y: Ataxia-telangiectasia, ATM, and genomic stability: maintaining a delicate balance. Two international workshops on ataxia-telangiectasia, related disorders, and the ATM protein. Biochim Biophys Acta 1998, 1378:R11-R18. This is an excellent review of the ATM gene and the ATM protein.
34. 34 Zakian VA: ATM-related genes: what do they tell us about functions of the human gene? Cell 1995, 82:685-687.
35. 35 Hoekstra MF: Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Curr Opin Genet Dev 1997, 7:170-175.
36. 36 Swift M, Reitnauer PJ, Morrell D, Chase CL: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987, 316:1289-1294.
37. 37 Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991, 325:1831-1836.
38. 38 Pippard EC, Hall AJ, Barker DJ, Bridges BA: Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 1988, 48:2929-2932.
39. 39 Vorechovsky I, Luo L, Lindblom A, Negrini M, Webster AD, Croce CM, Hammarstrom L: ATM mutations in cancer families. Cancer Res 1996, 56:4130-4133.
40. 40 FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, et al.: Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997, 15:307-310.
41. 41 Wooster R, Ford D, Mangion J, Ponder BA, Peto J, Easton DF, Stratton MR: Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 1993, 92:91-94.
42. 42 Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996, 92:130-134.
43. 43 Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A: The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998, 58:1376-1379. This study suggests that heterozygous ATM mutations make a minimal contribution to familial breast cancer and indicates that ATM is not likely to act as a tumor suppressor.
44. 44 Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994, 66(suppl):177-182.
45. 45 Corteiss V, Ingles S, Millikan R, Diep A, Gatti RA, Richardson L, et al.: Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. Cancer Res 1993, 53:5083-5086.
46. 46 Eighth International Workshop on Ataxia-Telangiectasia: Selected abstracts from the Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas, Nevada, USA, 1999.
47. 47 Janin N, Andrieu N, Ossian K, Lauge A, Croquette MF, Griscelli C, et al.: Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 1999, 80:1042-1045. This study agrees with others that indicate an increased risk for breast cancer in A-T heterozygotes.
48. 48 McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, Lennox GG, Taylor MR: Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 1996, 59:320-330.
49. 49 Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, et al.: ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998, 62:334-345.
50. 50 Slamon DJ, Clark GM: Amplification of c-erbB-2 and aggressive human breast tumors. Science 1988, 240:1795-1798.
51. 51 Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K: Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 1995, 6:135-145.
52. 52 Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S: Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993, 366:473-475.
53. 53 Siwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, et al.: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994, 269:14661-14665.
54. 54 King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J: Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J 1988, 7:1647-1651.
55. 55 Ross JA, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells (Dayt) 1998, 16:413-428. This is an excellent and comprehensive review of HER-2/neu studies correlating HER-2/neu abnormalities with prognosis, breast cancer, and response to therapy. Associated therapies are also reviewed.
56. 56 Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
57. 57 Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266.
58. 58 Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R: Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998, 273:28238-28246. This study investigates the mechanisms by which heregulin signaling may participate in the acquisition of an invasive phenotype in breast cancer.
59. 59 Tan M, Grijalva R, Yu D: Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res 1999, 59:1620-1625. The mechanism of heregulin signaling of HER-2/neu receptors and the invasive properties of breast cancer cells are investigated.
60. 60 Behrens J, Mareel MM, Van Roy FM, Birchmeier W: Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989, 108:2435-2447.
61. 61 Vleminckx K, Vakaet L, Jr, Mareel M, Fiers W, van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66:107-119.
62. 62 Glinsky GV: Cell adhesion and metastasis: is the site specificity of cancer metastasis determined by leukocyte-endothelial cell recognition and adhesion? Crit Rev Oncol Hematol 1993, 14:229-277.
63. 63 Raz A, Lotan R: Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 1987, 6:433-452.
64. 64 Siegel PM, Ryan ED, Cardiff RD, Muller Wj: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999, 18:2149-2164. This study suggests that co-expression of HER-2/neu and HER-3, as well as mutation in the HER-2/neu receptor may play a role in breast cancer development.